Automated Glory: $BNGO Rises +5.10% with Trader Robot Precision
In the ever-evolving landscape of active trading, AI-driven robots have become key players, providing insights and executing trades with precision. In this article, we delve into the recent performance of AI trading bots, particularly those accessible at "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)," which demonstrated their prowess by generating a notable +5.10% gain while trading BNGO over the past week.
BNGO's RSI Indicator Signals Transition
One crucial aspect of BNGO's recent trading activity is the Relative Strength Index (RSI) oscillator, which moved out of the overbought zone on December 29, 2023. This shift suggests a potential reversal from an upward trend to a downward one. Tickeron's A.I.dvisor, in analyzing similar instances, found that in 19 out of 20 cases where the RSI moved out of the overbought zone, the stock experienced a subsequent decline. This statistical observation gives traders a 90% likelihood of a downward move, prompting considerations for selling the stock or exploring put options.
Earnings Snapshot and Market Capitalization
Examining the last earnings report on November 09 reveals a notable -100 cents earnings per share, missing the estimated -97 cents. With 1.74 million shares outstanding, BNGO's current market capitalization stands at 59.43 million. It's crucial to note that this performance places BNGO within the Medical Specialties Industry, where the average market capitalization is 6.46 billion. Comparatively, BNGO's market cap appears significantly smaller, highlighting its distinct position within the industry.
Market Cap Comparisons
The Medical Specialties Industry presents a diverse range of market capitalizations, from 27 million to a staggering 3.82 trillion. Noteworthy companies in this sector include MKYSF with the highest valuation at 3.82 trillion and FOGCF at the lower end with a valuation of 27 million. BNGO's market cap, situated at 59.43 million, positions it within the mid-range of this industry spectrum.
Price Movements in the Industry
Understanding the broader market trends in the Medical Specialties Industry is essential. On average, weekly price growth for these stocks remained at 0%, while monthly growth registered at 11%, and quarterly growth at -6%. Within this spectrum, TIPS stood out with an impressive 286% price growth, while NMRD experienced a significant fall at -63%.
Volume Insights
Volume dynamics play a crucial role in understanding market activity. Across the Medical Specialties Industry, the average weekly volume growth was 127%, with monthly growth at 55%, and quarterly growth at 161%. These figures underscore the dynamic nature of trading within this sector and suggest heightened investor interest and participation.
The recent performance of AI trading bots, particularly in handling BNGO amidst changing market conditions, underscores the importance of adapting to evolving trends.
Contributor
BNGO sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for BNGO moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 164 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 39 of 62 cases where BNGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for BNGO moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In 11 of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNGO as a result. In 75 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for BNGO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
BNGO broke above its upper Bollinger Band on September 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.626) is normal, around the industry mean (5.011). P/E Ratio (0.002) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BNGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technologies for analysis of large biological molecules
Industry PharmaceuticalsOther
Advertisement